thioredoxin 2 Search Results


thioredoxin 2 antibody / txn2  (NSJ Bioreagents)
99
NSJ Bioreagents thioredoxin 2 antibody / txn2
Thioredoxin 2 Antibody / Txn2, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/thioredoxin+2/Thioredoxin+2+Antibody+%2F+TXN2/custom%40rq5639%4039205194
Average 99 stars, based on 1 article reviews
thioredoxin 2 antibody / txn2 - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
txn2  (Proteintech)
93
Proteintech txn2
Upregulation of the thioredoxin/peroxiredoxin pathway in DTP cells A) LNCaP epiDTP or enzDTP cells were treated for 48 h with EPI001 (EPI 50 µM) or enzalutamide (ENZ 60 µM), respectively, plus each ninety‐three drugs (10 µM) identified in Figure . Experiments identified 9 drugs that reduced cell survival below 70%. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. B) The highest concentration that does not affect LNCaP cell viability (IC 0 ) was determined for the above 9 drugs. Subsequently, LNCaP epiDTP or enzDTP cells were treated with each drug (IC 0 ) with or without EPI001 (EPI 50 µM) or enzalutamide (ENZ 60 µM) for 48 h. Additive or synergistic effects were seen for all nine drugs. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. C) Combination indexes (CI) of nine drugs were measured. A CI of less than, equal to, and more than 1 indicates synergy, additivity, and antagonism, respectively. D) 22Rv1 cells that are resistant to ENZ were treated for 48 h with ENZ (60 µM), each of the 9 drugs identified above, or in combinations. Results indicated that all 9 drugs either alone or in combination with ENZ could reduce cell survival. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. E) Diagram portrays the thioredoxin/peroxiredoxin pathway and up‐regulation of key proteins (red color) in DTP cells. F: Confirmation of proteomics results (TXNRD1, TXNRD2, TXNRD3, <t>TXN2,</t> and PRDX5) by Western blotting. GAPDH protein is used as the loading control. Data are expressed as mean ± std of triplicates. One‐way ANOVA with the Turkey test was performed. p <0.05 was considered significant and indicated by different letters.
Txn2, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/thioredoxin+2/TRX2+Antibody/pmc10916659-233-34-65
Average 93 stars, based on 1 article reviews
txn2 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
trx 2  (Cell Signaling Technology Inc)
94
Cell Signaling Technology Inc trx 2
Upregulation of the thioredoxin/peroxiredoxin pathway in DTP cells A) LNCaP epiDTP or enzDTP cells were treated for 48 h with EPI001 (EPI 50 µM) or enzalutamide (ENZ 60 µM), respectively, plus each ninety‐three drugs (10 µM) identified in Figure . Experiments identified 9 drugs that reduced cell survival below 70%. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. B) The highest concentration that does not affect LNCaP cell viability (IC 0 ) was determined for the above 9 drugs. Subsequently, LNCaP epiDTP or enzDTP cells were treated with each drug (IC 0 ) with or without EPI001 (EPI 50 µM) or enzalutamide (ENZ 60 µM) for 48 h. Additive or synergistic effects were seen for all nine drugs. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. C) Combination indexes (CI) of nine drugs were measured. A CI of less than, equal to, and more than 1 indicates synergy, additivity, and antagonism, respectively. D) 22Rv1 cells that are resistant to ENZ were treated for 48 h with ENZ (60 µM), each of the 9 drugs identified above, or in combinations. Results indicated that all 9 drugs either alone or in combination with ENZ could reduce cell survival. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. E) Diagram portrays the thioredoxin/peroxiredoxin pathway and up‐regulation of key proteins (red color) in DTP cells. F: Confirmation of proteomics results (TXNRD1, TXNRD2, TXNRD3, <t>TXN2,</t> and PRDX5) by Western blotting. GAPDH protein is used as the loading control. Data are expressed as mean ± std of triplicates. One‐way ANOVA with the Turkey test was performed. p <0.05 was considered significant and indicated by different letters.
Trx 2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/thioredoxin+2/Thioredoxin+2+Rabbit+mAb/pm31467086-68-45-47
Average 94 stars, based on 1 article reviews
trx 2 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
thioredoxin reductase 2  (Biorbyt)
90
Biorbyt thioredoxin reductase 2
Upregulation of the thioredoxin/peroxiredoxin pathway in DTP cells A) LNCaP epiDTP or enzDTP cells were treated for 48 h with EPI001 (EPI 50 µM) or enzalutamide (ENZ 60 µM), respectively, plus each ninety‐three drugs (10 µM) identified in Figure . Experiments identified 9 drugs that reduced cell survival below 70%. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. B) The highest concentration that does not affect LNCaP cell viability (IC 0 ) was determined for the above 9 drugs. Subsequently, LNCaP epiDTP or enzDTP cells were treated with each drug (IC 0 ) with or without EPI001 (EPI 50 µM) or enzalutamide (ENZ 60 µM) for 48 h. Additive or synergistic effects were seen for all nine drugs. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. C) Combination indexes (CI) of nine drugs were measured. A CI of less than, equal to, and more than 1 indicates synergy, additivity, and antagonism, respectively. D) 22Rv1 cells that are resistant to ENZ were treated for 48 h with ENZ (60 µM), each of the 9 drugs identified above, or in combinations. Results indicated that all 9 drugs either alone or in combination with ENZ could reduce cell survival. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. E) Diagram portrays the thioredoxin/peroxiredoxin pathway and up‐regulation of key proteins (red color) in DTP cells. F: Confirmation of proteomics results (TXNRD1, TXNRD2, TXNRD3, <t>TXN2,</t> and PRDX5) by Western blotting. GAPDH protein is used as the loading control. Data are expressed as mean ± std of triplicates. One‐way ANOVA with the Turkey test was performed. p <0.05 was considered significant and indicated by different letters.
Thioredoxin Reductase 2, supplied by Biorbyt, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/thioredoxin+2/Thioredoxin+2+antibody/10__1016_slash_j__jpap__2021__100053-99-20-18
Average 90 stars, based on 1 article reviews
thioredoxin reductase 2 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
uk txn2 goat af3254 r d systems  (R&D Systems)
90
R&D Systems uk txn2 goat af3254 r d systems
Upregulation of the thioredoxin/peroxiredoxin pathway in DTP cells A) LNCaP epiDTP or enzDTP cells were treated for 48 h with EPI001 (EPI 50 µM) or enzalutamide (ENZ 60 µM), respectively, plus each ninety‐three drugs (10 µM) identified in Figure . Experiments identified 9 drugs that reduced cell survival below 70%. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. B) The highest concentration that does not affect LNCaP cell viability (IC 0 ) was determined for the above 9 drugs. Subsequently, LNCaP epiDTP or enzDTP cells were treated with each drug (IC 0 ) with or without EPI001 (EPI 50 µM) or enzalutamide (ENZ 60 µM) for 48 h. Additive or synergistic effects were seen for all nine drugs. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. C) Combination indexes (CI) of nine drugs were measured. A CI of less than, equal to, and more than 1 indicates synergy, additivity, and antagonism, respectively. D) 22Rv1 cells that are resistant to ENZ were treated for 48 h with ENZ (60 µM), each of the 9 drugs identified above, or in combinations. Results indicated that all 9 drugs either alone or in combination with ENZ could reduce cell survival. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. E) Diagram portrays the thioredoxin/peroxiredoxin pathway and up‐regulation of key proteins (red color) in DTP cells. F: Confirmation of proteomics results (TXNRD1, TXNRD2, TXNRD3, <t>TXN2,</t> and PRDX5) by Western blotting. GAPDH protein is used as the loading control. Data are expressed as mean ± std of triplicates. One‐way ANOVA with the Turkey test was performed. p <0.05 was considered significant and indicated by different letters.
Uk Txn2 Goat Af3254 R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/thioredoxin+2/Human%2FMouse%2FRat+Thioredoxin-2+Antibody/pmc04726503__pgen__1005800__s009-0-62-66
Average 90 stars, based on 1 article reviews
uk txn2 goat af3254 r d systems - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
thioredoxin 2  (Novus Biologicals)
90
Novus Biologicals thioredoxin 2
Upregulation of the thioredoxin/peroxiredoxin pathway in DTP cells A) LNCaP epiDTP or enzDTP cells were treated for 48 h with EPI001 (EPI 50 µM) or enzalutamide (ENZ 60 µM), respectively, plus each ninety‐three drugs (10 µM) identified in Figure . Experiments identified 9 drugs that reduced cell survival below 70%. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. B) The highest concentration that does not affect LNCaP cell viability (IC 0 ) was determined for the above 9 drugs. Subsequently, LNCaP epiDTP or enzDTP cells were treated with each drug (IC 0 ) with or without EPI001 (EPI 50 µM) or enzalutamide (ENZ 60 µM) for 48 h. Additive or synergistic effects were seen for all nine drugs. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. C) Combination indexes (CI) of nine drugs were measured. A CI of less than, equal to, and more than 1 indicates synergy, additivity, and antagonism, respectively. D) 22Rv1 cells that are resistant to ENZ were treated for 48 h with ENZ (60 µM), each of the 9 drugs identified above, or in combinations. Results indicated that all 9 drugs either alone or in combination with ENZ could reduce cell survival. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. E) Diagram portrays the thioredoxin/peroxiredoxin pathway and up‐regulation of key proteins (red color) in DTP cells. F: Confirmation of proteomics results (TXNRD1, TXNRD2, TXNRD3, <t>TXN2,</t> and PRDX5) by Western blotting. GAPDH protein is used as the loading control. Data are expressed as mean ± std of triplicates. One‐way ANOVA with the Turkey test was performed. p <0.05 was considered significant and indicated by different letters.
Thioredoxin 2, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/thioredoxin+2/Thioredoxin-2+Antibody/pm34547371-64-36-38
Average 90 stars, based on 1 article reviews
thioredoxin 2 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
trx2  (R&D Systems)
90
R&D Systems trx2
Upregulation of the thioredoxin/peroxiredoxin pathway in DTP cells A) LNCaP epiDTP or enzDTP cells were treated for 48 h with EPI001 (EPI 50 µM) or enzalutamide (ENZ 60 µM), respectively, plus each ninety‐three drugs (10 µM) identified in Figure . Experiments identified 9 drugs that reduced cell survival below 70%. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. B) The highest concentration that does not affect LNCaP cell viability (IC 0 ) was determined for the above 9 drugs. Subsequently, LNCaP epiDTP or enzDTP cells were treated with each drug (IC 0 ) with or without EPI001 (EPI 50 µM) or enzalutamide (ENZ 60 µM) for 48 h. Additive or synergistic effects were seen for all nine drugs. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. C) Combination indexes (CI) of nine drugs were measured. A CI of less than, equal to, and more than 1 indicates synergy, additivity, and antagonism, respectively. D) 22Rv1 cells that are resistant to ENZ were treated for 48 h with ENZ (60 µM), each of the 9 drugs identified above, or in combinations. Results indicated that all 9 drugs either alone or in combination with ENZ could reduce cell survival. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. E) Diagram portrays the thioredoxin/peroxiredoxin pathway and up‐regulation of key proteins (red color) in DTP cells. F: Confirmation of proteomics results (TXNRD1, TXNRD2, TXNRD3, <t>TXN2,</t> and PRDX5) by Western blotting. GAPDH protein is used as the loading control. Data are expressed as mean ± std of triplicates. One‐way ANOVA with the Turkey test was performed. p <0.05 was considered significant and indicated by different letters.
Trx2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/thioredoxin+2/Human%2FMouse%2FRat+Thioredoxin-2+Antibody/pmc04150915-65-37-42
Average 90 stars, based on 1 article reviews
trx2 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
trx2 antibody  (ABclonal Biotechnology)
93
ABclonal Biotechnology trx2 antibody
Txnip was regulated by Zbtb16 and combined with <t>Trx2</t> in mitochondria. A Top ten enriched biological process terms by GO analysis in db/ + and db/db mouse atria. B Intersection of RNA-seq and CUT&Tag assay results of db/ + and db/db mouse atria ( n = 3 in each group). C RT-PCR analysis of Txnip mRNA in db/ + and db/db mouse atria ( n = 5 for each group). D CUT&Tag-PCR analysis of Txnip promoter binding region ( n = 3 in each group). E CUT&Tag IGV visual analysis of Zbtb16 binding peak at the Txnip promoter region in db/ + and db/db mouse atria. F , G Binding site sequences of predicted Txnip promoter region ( F ) and luciferase reporter assay confirmation ( G ). H–J The respective WB images of cytoplasm and mitochondria Txnip expression ( H ) in db/ + and db/db mouse atria, ( I , J) is the quantitative analysis of ( H ) ( n = 6 for each group). K co-IP assay of Txnip-Trx2 combination in mitochondrion ( n = 6 for each group). L , M Immunofluorescence co-staining for COX IV with Txnip in db/ + and db/db mouse atrial myocytes ( L ), ( M ) is the quantitative analysis of ( L ) ( n = 6 for each group). Bar = 50 μm. Data in ( C , D , I , J and M ) were analyzed by two-tailed student t test. Data in G were analyzed by one-way ANOVA with Bonferroni’s multiple comparisons test
Trx2 Antibody, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/thioredoxin+2/Thioredoxin+2+Rabbit+mAb/pmc10864461-69-12-15
Average 93 stars, based on 1 article reviews
trx2 antibody - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
serum trx 1 level  (Boster Bio)
90
Boster Bio serum trx 1 level
Txnip was regulated by Zbtb16 and combined with <t>Trx2</t> in mitochondria. A Top ten enriched biological process terms by GO analysis in db/ + and db/db mouse atria. B Intersection of RNA-seq and CUT&Tag assay results of db/ + and db/db mouse atria ( n = 3 in each group). C RT-PCR analysis of Txnip mRNA in db/ + and db/db mouse atria ( n = 5 for each group). D CUT&Tag-PCR analysis of Txnip promoter binding region ( n = 3 in each group). E CUT&Tag IGV visual analysis of Zbtb16 binding peak at the Txnip promoter region in db/ + and db/db mouse atria. F , G Binding site sequences of predicted Txnip promoter region ( F ) and luciferase reporter assay confirmation ( G ). H–J The respective WB images of cytoplasm and mitochondria Txnip expression ( H ) in db/ + and db/db mouse atria, ( I , J) is the quantitative analysis of ( H ) ( n = 6 for each group). K co-IP assay of Txnip-Trx2 combination in mitochondrion ( n = 6 for each group). L , M Immunofluorescence co-staining for COX IV with Txnip in db/ + and db/db mouse atrial myocytes ( L ), ( M ) is the quantitative analysis of ( L ) ( n = 6 for each group). Bar = 50 μm. Data in ( C , D , I , J and M ) were analyzed by two-tailed student t test. Data in G were analyzed by one-way ANOVA with Bonferroni’s multiple comparisons test
Serum Trx 1 Level, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/thioredoxin+2/Mouse+Thioredoxin-1+Recombinant+Protein/10__1016_slash_j__ejbas__2018__01__001-42-0-21
Average 90 stars, based on 1 article reviews
serum trx 1 level - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
txn2  (Sino Biological)
89
Sino Biological txn2
Txnip was regulated by Zbtb16 and combined with <t>Trx2</t> in mitochondria. A Top ten enriched biological process terms by GO analysis in db/ + and db/db mouse atria. B Intersection of RNA-seq and CUT&Tag assay results of db/ + and db/db mouse atria ( n = 3 in each group). C RT-PCR analysis of Txnip mRNA in db/ + and db/db mouse atria ( n = 5 for each group). D CUT&Tag-PCR analysis of Txnip promoter binding region ( n = 3 in each group). E CUT&Tag IGV visual analysis of Zbtb16 binding peak at the Txnip promoter region in db/ + and db/db mouse atria. F , G Binding site sequences of predicted Txnip promoter region ( F ) and luciferase reporter assay confirmation ( G ). H–J The respective WB images of cytoplasm and mitochondria Txnip expression ( H ) in db/ + and db/db mouse atria, ( I , J) is the quantitative analysis of ( H ) ( n = 6 for each group). K co-IP assay of Txnip-Trx2 combination in mitochondrion ( n = 6 for each group). L , M Immunofluorescence co-staining for COX IV with Txnip in db/ + and db/db mouse atrial myocytes ( L ), ( M ) is the quantitative analysis of ( L ) ( n = 6 for each group). Bar = 50 μm. Data in ( C , D , I , J and M ) were analyzed by two-tailed student t test. Data in G were analyzed by one-way ANOVA with Bonferroni’s multiple comparisons test
Txn2, supplied by Sino Biological, used in various techniques. Bioz Stars score: 89/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/thioredoxin+2/txn2/custom%40txn2%4035883870
Average 89 stars, based on 1 article reviews
txn2 - by Bioz Stars, 2026-10
89/100 stars
  Buy from Supplier
thioredoxin  (ProSci Incorporated)
94
ProSci Incorporated thioredoxin
Txnip was regulated by Zbtb16 and combined with <t>Trx2</t> in mitochondria. A Top ten enriched biological process terms by GO analysis in db/ + and db/db mouse atria. B Intersection of RNA-seq and CUT&Tag assay results of db/ + and db/db mouse atria ( n = 3 in each group). C RT-PCR analysis of Txnip mRNA in db/ + and db/db mouse atria ( n = 5 for each group). D CUT&Tag-PCR analysis of Txnip promoter binding region ( n = 3 in each group). E CUT&Tag IGV visual analysis of Zbtb16 binding peak at the Txnip promoter region in db/ + and db/db mouse atria. F , G Binding site sequences of predicted Txnip promoter region ( F ) and luciferase reporter assay confirmation ( G ). H–J The respective WB images of cytoplasm and mitochondria Txnip expression ( H ) in db/ + and db/db mouse atria, ( I , J) is the quantitative analysis of ( H ) ( n = 6 for each group). K co-IP assay of Txnip-Trx2 combination in mitochondrion ( n = 6 for each group). L , M Immunofluorescence co-staining for COX IV with Txnip in db/ + and db/db mouse atrial myocytes ( L ), ( M ) is the quantitative analysis of ( L ) ( n = 6 for each group). Bar = 50 μm. Data in ( C , D , I , J and M ) were analyzed by two-tailed student t test. Data in G were analyzed by one-way ANOVA with Bonferroni’s multiple comparisons test
Thioredoxin, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/thioredoxin+2/Thioredoxin+Antibody/pm41846099-65-11-14
Average 94 stars, based on 1 article reviews
thioredoxin - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

Image Search Results


Upregulation of the thioredoxin/peroxiredoxin pathway in DTP cells A) LNCaP epiDTP or enzDTP cells were treated for 48 h with EPI001 (EPI 50 µM) or enzalutamide (ENZ 60 µM), respectively, plus each ninety‐three drugs (10 µM) identified in Figure . Experiments identified 9 drugs that reduced cell survival below 70%. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. B) The highest concentration that does not affect LNCaP cell viability (IC 0 ) was determined for the above 9 drugs. Subsequently, LNCaP epiDTP or enzDTP cells were treated with each drug (IC 0 ) with or without EPI001 (EPI 50 µM) or enzalutamide (ENZ 60 µM) for 48 h. Additive or synergistic effects were seen for all nine drugs. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. C) Combination indexes (CI) of nine drugs were measured. A CI of less than, equal to, and more than 1 indicates synergy, additivity, and antagonism, respectively. D) 22Rv1 cells that are resistant to ENZ were treated for 48 h with ENZ (60 µM), each of the 9 drugs identified above, or in combinations. Results indicated that all 9 drugs either alone or in combination with ENZ could reduce cell survival. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. E) Diagram portrays the thioredoxin/peroxiredoxin pathway and up‐regulation of key proteins (red color) in DTP cells. F: Confirmation of proteomics results (TXNRD1, TXNRD2, TXNRD3, TXN2, and PRDX5) by Western blotting. GAPDH protein is used as the loading control. Data are expressed as mean ± std of triplicates. One‐way ANOVA with the Turkey test was performed. p <0.05 was considered significant and indicated by different letters.

Journal: Advanced Science

Article Title: Identification of PRDX5 as A Target for The Treatment of Castration‐Resistant Prostate Cancer

doi: 10.1002/advs.202304939

Figure Lengend Snippet: Upregulation of the thioredoxin/peroxiredoxin pathway in DTP cells A) LNCaP epiDTP or enzDTP cells were treated for 48 h with EPI001 (EPI 50 µM) or enzalutamide (ENZ 60 µM), respectively, plus each ninety‐three drugs (10 µM) identified in Figure . Experiments identified 9 drugs that reduced cell survival below 70%. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. B) The highest concentration that does not affect LNCaP cell viability (IC 0 ) was determined for the above 9 drugs. Subsequently, LNCaP epiDTP or enzDTP cells were treated with each drug (IC 0 ) with or without EPI001 (EPI 50 µM) or enzalutamide (ENZ 60 µM) for 48 h. Additive or synergistic effects were seen for all nine drugs. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. C) Combination indexes (CI) of nine drugs were measured. A CI of less than, equal to, and more than 1 indicates synergy, additivity, and antagonism, respectively. D) 22Rv1 cells that are resistant to ENZ were treated for 48 h with ENZ (60 µM), each of the 9 drugs identified above, or in combinations. Results indicated that all 9 drugs either alone or in combination with ENZ could reduce cell survival. Each data point represents the average of three independent experiments and is expressed as a percentage of viable cells relative to untreated controls as measured by CCK‐8 assay. Standard deviations are less than 5%. E) Diagram portrays the thioredoxin/peroxiredoxin pathway and up‐regulation of key proteins (red color) in DTP cells. F: Confirmation of proteomics results (TXNRD1, TXNRD2, TXNRD3, TXN2, and PRDX5) by Western blotting. GAPDH protein is used as the loading control. Data are expressed as mean ± std of triplicates. One‐way ANOVA with the Turkey test was performed. p <0.05 was considered significant and indicated by different letters.

Article Snippet: PRDX5 (67599‐1‐Ig; 1:2000), CDKN1A (p21) (60214‐1‐Ig; 1:1000), Cyclin E1 (CCNE1) (11554‐1‐AP; 1:1000), Cyclin B1 (CCNB1) (67686‐1‐Ig; 1:5000), CDC6 (11640‐1‐AP; 1:2000), CDC2 (CDK1) (19532‐1‐AP; 1:1000), TXNRD1 (67728‐1‐Ig; 1:10 000), TXNRD2 (16360‐1‐AP; 1:3000), TXNRD3 (19517‐1‐AP; 1:2000), TXN2 (13089‐1‐AP; 1:1000), NSE (66150‐1‐Ig; 1:10 000), CgA (60135‐2‐Ig; 1:3000), CgB (14968‐1‐AP; 1:2000), PTHrP (29115‐1‐AP; 1:800), AMACR (15918‐1‐AP; 1:500), GAPDH (60004‐1‐Ig; 1:50 000), β‐ACTIN (66009‐1‐Ig; 1:10 000) antibodies were purchased from Proteintech Group (IL, US). β‐TUBLIN (86 298; 1:10 000) antibody was purchased from Cell Signaling Technology (MA, US).

Techniques: CCK-8 Assay, Concentration Assay, Western Blot, Control

Txnip was regulated by Zbtb16 and combined with Trx2 in mitochondria. A Top ten enriched biological process terms by GO analysis in db/ + and db/db mouse atria. B Intersection of RNA-seq and CUT&Tag assay results of db/ + and db/db mouse atria ( n = 3 in each group). C RT-PCR analysis of Txnip mRNA in db/ + and db/db mouse atria ( n = 5 for each group). D CUT&Tag-PCR analysis of Txnip promoter binding region ( n = 3 in each group). E CUT&Tag IGV visual analysis of Zbtb16 binding peak at the Txnip promoter region in db/ + and db/db mouse atria. F , G Binding site sequences of predicted Txnip promoter region ( F ) and luciferase reporter assay confirmation ( G ). H–J The respective WB images of cytoplasm and mitochondria Txnip expression ( H ) in db/ + and db/db mouse atria, ( I , J) is the quantitative analysis of ( H ) ( n = 6 for each group). K co-IP assay of Txnip-Trx2 combination in mitochondrion ( n = 6 for each group). L , M Immunofluorescence co-staining for COX IV with Txnip in db/ + and db/db mouse atrial myocytes ( L ), ( M ) is the quantitative analysis of ( L ) ( n = 6 for each group). Bar = 50 μm. Data in ( C , D , I , J and M ) were analyzed by two-tailed student t test. Data in G were analyzed by one-way ANOVA with Bonferroni’s multiple comparisons test

Journal: Cellular and Molecular Life Sciences

Article Title: Zbtb16 increases susceptibility of atrial fibrillation in type 2 diabetic mice via Txnip-Trx2 signaling

doi: 10.1007/s00018-024-05125-2

Figure Lengend Snippet: Txnip was regulated by Zbtb16 and combined with Trx2 in mitochondria. A Top ten enriched biological process terms by GO analysis in db/ + and db/db mouse atria. B Intersection of RNA-seq and CUT&Tag assay results of db/ + and db/db mouse atria ( n = 3 in each group). C RT-PCR analysis of Txnip mRNA in db/ + and db/db mouse atria ( n = 5 for each group). D CUT&Tag-PCR analysis of Txnip promoter binding region ( n = 3 in each group). E CUT&Tag IGV visual analysis of Zbtb16 binding peak at the Txnip promoter region in db/ + and db/db mouse atria. F , G Binding site sequences of predicted Txnip promoter region ( F ) and luciferase reporter assay confirmation ( G ). H–J The respective WB images of cytoplasm and mitochondria Txnip expression ( H ) in db/ + and db/db mouse atria, ( I , J) is the quantitative analysis of ( H ) ( n = 6 for each group). K co-IP assay of Txnip-Trx2 combination in mitochondrion ( n = 6 for each group). L , M Immunofluorescence co-staining for COX IV with Txnip in db/ + and db/db mouse atrial myocytes ( L ), ( M ) is the quantitative analysis of ( L ) ( n = 6 for each group). Bar = 50 μm. Data in ( C , D , I , J and M ) were analyzed by two-tailed student t test. Data in G were analyzed by one-way ANOVA with Bonferroni’s multiple comparisons test

Article Snippet: Whole-cell lysates were mixed with Txnip (14715S; Cell Signaling Technology, Danvers, MA), Trx2 antibody (A4424; ABclonal, Wuhan, China) (20 μg/mL) or IgG antibody (ab172730; Abcam, Cambridge, UK) for 1 h at room temperature.

Techniques: RNA Sequencing, Reverse Transcription Polymerase Chain Reaction, Binding Assay, Luciferase, Reporter Assay, Expressing, Co-Immunoprecipitation Assay, Immunofluorescence, Staining, Two Tailed Test

Zbtb16 or Txnip knockdown reduced combination of Txnip-Trx2 and improved Trx2 function. A Immunofluorescence co-staining for α-Actinin with Flag in mouse heart. B , C The respective WB images and quantitative analysis of Zbtb16 expression ( B ) in db/ + and db/db mouse atrial myocytes and Txnip expression ( C ) in mitochondria ( n = 6 for each group). D , E co-IP assay of Txnip-Trx2 combination in mitochondria after Zbtb16-KD ( D ) or Txnip-KD ( E ) ( n = 6 for each group). F Analysis of Trx2 activity in mitochondria of db/ + and db/db mouse atria ( n = 6 for each group). Bar = 1 μm. Data in ( B , C , and F ) were analyzed by two-way ANOVA with Bonferroni’s multiple comparisons test. KD knockdown

Journal: Cellular and Molecular Life Sciences

Article Title: Zbtb16 increases susceptibility of atrial fibrillation in type 2 diabetic mice via Txnip-Trx2 signaling

doi: 10.1007/s00018-024-05125-2

Figure Lengend Snippet: Zbtb16 or Txnip knockdown reduced combination of Txnip-Trx2 and improved Trx2 function. A Immunofluorescence co-staining for α-Actinin with Flag in mouse heart. B , C The respective WB images and quantitative analysis of Zbtb16 expression ( B ) in db/ + and db/db mouse atrial myocytes and Txnip expression ( C ) in mitochondria ( n = 6 for each group). D , E co-IP assay of Txnip-Trx2 combination in mitochondria after Zbtb16-KD ( D ) or Txnip-KD ( E ) ( n = 6 for each group). F Analysis of Trx2 activity in mitochondria of db/ + and db/db mouse atria ( n = 6 for each group). Bar = 1 μm. Data in ( B , C , and F ) were analyzed by two-way ANOVA with Bonferroni’s multiple comparisons test. KD knockdown

Article Snippet: Whole-cell lysates were mixed with Txnip (14715S; Cell Signaling Technology, Danvers, MA), Trx2 antibody (A4424; ABclonal, Wuhan, China) (20 μg/mL) or IgG antibody (ab172730; Abcam, Cambridge, UK) for 1 h at room temperature.

Techniques: Knockdown, Immunofluorescence, Staining, Expressing, Co-Immunoprecipitation Assay, Activity Assay

Zbtb16 or Txnip knockdown ameliorated Trx2 activity and reduced ROS-induced CaMKIIδ activation in HL-1 cells. A , B co-IP assay of Txnip-Trx2 combination in mitochondria after Zbtb16-KD ( A ) or Txnip-KD ( B ) in HL-1 cells ( n = 6 for each group). C Analysis of Trx2 activity in mitochondria of HL-1 cells ( n = 6 for each group). D , E Representative images ( D ) and quantitative analysis ( E ) of ROS level measured by DHE staining in HL-1 cells ( n = 18). Bar = 200 μm. F – J Representative WB images ( F ) and quantitative analysis in HL-1 cells of CaMKIIδ ( G ), RyR2 ( H ), PLB ( I ), and SERCA2a ( J ) with Zbtb16- KD, Txnip-KD or Mito-TEMPO treatment ( n = 6 for each group). Data in ( C , E and G – J ) were analyzed by two-way ANOVA with Bonferroni’s multiple comparisons test. KD knockdown

Journal: Cellular and Molecular Life Sciences

Article Title: Zbtb16 increases susceptibility of atrial fibrillation in type 2 diabetic mice via Txnip-Trx2 signaling

doi: 10.1007/s00018-024-05125-2

Figure Lengend Snippet: Zbtb16 or Txnip knockdown ameliorated Trx2 activity and reduced ROS-induced CaMKIIδ activation in HL-1 cells. A , B co-IP assay of Txnip-Trx2 combination in mitochondria after Zbtb16-KD ( A ) or Txnip-KD ( B ) in HL-1 cells ( n = 6 for each group). C Analysis of Trx2 activity in mitochondria of HL-1 cells ( n = 6 for each group). D , E Representative images ( D ) and quantitative analysis ( E ) of ROS level measured by DHE staining in HL-1 cells ( n = 18). Bar = 200 μm. F – J Representative WB images ( F ) and quantitative analysis in HL-1 cells of CaMKIIδ ( G ), RyR2 ( H ), PLB ( I ), and SERCA2a ( J ) with Zbtb16- KD, Txnip-KD or Mito-TEMPO treatment ( n = 6 for each group). Data in ( C , E and G – J ) were analyzed by two-way ANOVA with Bonferroni’s multiple comparisons test. KD knockdown

Article Snippet: Whole-cell lysates were mixed with Txnip (14715S; Cell Signaling Technology, Danvers, MA), Trx2 antibody (A4424; ABclonal, Wuhan, China) (20 μg/mL) or IgG antibody (ab172730; Abcam, Cambridge, UK) for 1 h at room temperature.

Techniques: Knockdown, Activity Assay, Activation Assay, Co-Immunoprecipitation Assay, Staining

A working model of Zbtb16-induced DADs occurrence and AF development by Txnip-Trx2 signaling in db/db mice. Zbtb16-Txnip-Trx2 pathway contributed to AF development in db/db mice by excess ROS generation-induced CaMKIIδ overactivation, abnormal SR Ca 2+ release and DADs occurrence

Journal: Cellular and Molecular Life Sciences

Article Title: Zbtb16 increases susceptibility of atrial fibrillation in type 2 diabetic mice via Txnip-Trx2 signaling

doi: 10.1007/s00018-024-05125-2

Figure Lengend Snippet: A working model of Zbtb16-induced DADs occurrence and AF development by Txnip-Trx2 signaling in db/db mice. Zbtb16-Txnip-Trx2 pathway contributed to AF development in db/db mice by excess ROS generation-induced CaMKIIδ overactivation, abnormal SR Ca 2+ release and DADs occurrence

Article Snippet: Whole-cell lysates were mixed with Txnip (14715S; Cell Signaling Technology, Danvers, MA), Trx2 antibody (A4424; ABclonal, Wuhan, China) (20 μg/mL) or IgG antibody (ab172730; Abcam, Cambridge, UK) for 1 h at room temperature.

Techniques: